NEW YORK (AP) — Delcath Systems Inc. said Monday the Food and Drug Administration gave its developing liver cancer treatment doxorubicin orphan drug status. Orphan drug status is given to drugs aimed at rare conditions or conditions that have a lack of treatments on the market. Incentives include seven years of market exclusivity following FDA approval, assistance in clinical trial design, a reduction in user fees, and tax credits. Delcath focuses on using drug delivery technology that gives ultra-high doses of anticancer drugs to the liver.
Related Articles Read More >

The need for a data-driven culture in life sciences: What you don’t know can hurt you

The economics behind the Adderall shortage: Why low prices lead to scarcity
The battle of the bulge: Semaglutide and tirzapatide could be new weight-loss warriors
